Artificial Valve Endocarditis Reduction Trial (AVERT): Protocol of a multicenter randomized trial

Journal of Heart Valve Disease

Volumn 8, Issue 2, 1999, Pages 131-139

  Schaff, Hartzell ^a   Carrel, Thierry ^a   Steckelberg, James M ^a   Grunkemeier, Gary L ^a   Holubkov, Richard ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYESTER; SILVER;

ANGINA PECTORIS; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOCARDITIS; FEVER; FOLLOW UP; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAINT JUDE HEART VALVE PROSTHESIS;

EID: 0032948422     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Karchmer AW, Gibbons GW. Infections of prosthetic heart valves and vascular grafts. In Bisno AL, Waldvogel FA (ed.) Infection Associated with Indwelling Medical Devices. American Society for Microbiology, Washington DC, 1989:213-249
2. Karchmer AW, Dismukes WE, Buckley MJ, Austen WG. Late prosthetic valve endocarditis: Clinical features influencing therapy. Am J Med 1978;64:199-206
3. Cowgill LD, Addonizio VP, Hopeman AR, Harken AH. A practical approach to prosthetic valve endocarditis. Ann Thorac Surg 1987;43:450-457
4. Vlessis AA, Khaki A, Grunkemeier GL, Li HH, Starr A. Risk, diagnosis and management of prosthetic valve endocarditis: A review. J Heart Valve Dis 1997;6:443-465
5. Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis: Recommendations by the American Heart Association. JAMA 1997;277:1794-1801
6. Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. JAMA 1995;274:1706-1713
7. Tweden KS, Cameron JD, Razzouk AJ, et al. Silver modification of polyethylene terphthalate textiles for antimicrobial protection. Am Soc Artif Intern Organs J 1997;43:M475-M482
8. Tweden KS, Cameron JD, Razzouk AJ, Holmberg WR, Kelly SJ. Biocompatibility of silver-modified polyester for antimicrobial protection of prosthetic valves. J Heart Valve Dis 1997;6:553-561
9. Illingworth BL, Tweden K, Schroeder RF, Cameron JD. In vivo efficacy of silver-coated (Silzone) infection-resistant polyester fabric against a biofilm-producing bacteria, Staphylococcus epidermidis. J Heart Valve Dis 1998;7:524-530
10. Edmunds LH, Jr, Clarke RE, Cohn LH, Grunkemeier GL, Miller DC, Weisel RD. Guidelines for reporting morbidity and mortality after cardiac valvular operations. J Thorac Cardiovasc Surg 1996;112:708-711
11. Division of Cardiovascular Respiratory and Neurological Devices. Draft Replacement Heart Valve Guidance. Version 4.1, U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Devices and Radiological Health, 1994
12. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: Utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 1994;96:200-209
13. Hebert P. Treatment. In Kane RL (ed.). Understanding Health Care Outcomes Research. Aspen Publishers 1997:91-125